Bombardier Announces Unifor Local 112 and 673 Employees Renew 3-Year Collective Agreement

FSH-free versus FSH-primed infertility treatment of women with polycystic ovary syndrome using biphasic in vitro maturation: a randomized clinical trial

nCino Named a 2024 World’s Top FinTech Company by CNBC

Valeura Energy Inc.: Q2 2024 Operations and Financial Update

IVECO BUS wins a large contract in Austria for more than 900 buses

VistaJet flights are the newest global location to experience Beefbar’s award winning cuisine

EBC Financial Group (UK) Ltd CEO David Barrett on Navigating Offshore Success in the Global Brokerage Market Amid Tightening Onshore Regulations

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal

Notified -

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal

MedPro International Sponsors Medical Services to Over 300 Patients

VCI Global Announces Joint Venture With Cogia AG to Expand Secure Messaging Technology

Teledyne’s high-speed, high-resolution Contact Image Sensors are now available in color